SYDNEY, April 28, 2026, 08:04 AEST
AustralianSuper cut its voting power in Cochlear Limited to 5.02% from 7.24%, a filing lodged late Monday showed, leaving the retirement fund just above Australia’s key substantial-holder disclosure line after a brutal reset for the hearing-implant maker. The notice listed AustralianSuper’s present holding at 3.28 million ordinary shares, down from 4.73 million.
The filing matters now because it landed days after Cochlear slashed its profit outlook and as investors try to judge whether last week’s selloff has found a floor. Cochlear shares last traded at A$95.25 on Monday, down 2.16%, after closing at A$99.58 on Wednesday in a record 40.7% one-day fall.
A substantial holding is a disclosure category, not a takeover bid. In Australia, investors with relevant interests in voting shares representing 5% or more of a listed company’s votes generally must disclose those interests, and must also disclose certain later changes.
Cochlear last week cut its FY26 underlying net profit forecast to A$290 million to A$330 million from prior guidance of A$435 million to A$460 million. Underlying net profit strips out some items the company treats as outside normal operations. The company cited weaker developed-market implant demand, Middle East uncertainty, a stronger Australian dollar and costs tied to reshaping its cost base.
The downgrade was not just a miss. Reuters reported that the midpoint of the new guidance range was well below Visible Alpha’s A$402.5 million consensus estimate, while the stock’s Wednesday close was its weakest since March 2016.
Chief Executive Dig Howitt said adult and senior hearing loss was still being treated as a discretionary intervention, underlining Cochlear’s push to “medicalise hearing loss.” He also said the company remained confident in its “market leadership,” helped by adoption of its Nucleus Nexa system.
There are some offsets. Cochlear said services revenue rose 13% in constant currency in the third quarter, while acoustics revenue grew 11%. Constant currency means sales measured without exchange-rate moves, useful for a company with large offshore earnings.
Analysts and investors were harsher. Wilson Asset Management portfolio manager Anna Milne said the size of the downgrade and uncertainty around the recovery “shocked the market.” Jarden analyst Steve Wheen called the downgrade “far worse than anticipated,” while Bell Potter’s Richard Coppleson described the earnings cut as “extraordinary.” Wilson Asset Management
The competitive question is getting louder too. Jarden’s Wheen flagged pressure from Med-El and Advanced Bionics, saying Cochlear’s expected price premium was not holding in the United States, according to the same report. That matters because Cochlear’s investment case has long leaned on premium products, scale and high market share in implantable hearing devices.
But the risk is that the April downgrade is not the end of the reset. Cochlear said it may need up to A$10 million of receivables provisions tied to the Middle East conflict, expects lower production to hit gross margin by about A$20 million, sees cost-base reshaping costs of A$18 million to A$25 million, and faces an after-tax foreign-exchange drag of about A$25 million in the second half.
For now, Monday’s AustralianSuper notice is a fresh sign that large holders are still adjusting after the profit warning. The company has not said demand is structurally broken. The market is asking how long it takes to prove that.
